Kelsie Swisher
Psychiatric/Mental Health · Parkersburg, IANPI 1932652757
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $216,263 of the $235,304 with a category attached, or 91.9%. AbbVie accounts for 98.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $82,366 and has fallen 99.3% since, to $582 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 657 payments — averaging $358.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$232K
- Johnson & Johnson$512
- Neurocrine Biosciences, Inc.$446
- Otsuka America Pharmaceutical, Inc.$319
- Alkermes, Inc.$313
- Corium, LLC$257
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$216,26392%
- Travel & lodging$11,9005%
- Food & beverage$7,1413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 402 | $231,927 |
| Johnson & Johnson | 50 | $512 |
| Neurocrine Biosciences, Inc. | 57 | $446 |
| Otsuka America Pharmaceutical, Inc. | 28 | $319 |
| Alkermes, Inc. | 16 | $313 |
| Corium, LLC | 20 | $257 |
| Sunovion Pharmaceuticals Inc. | 13 | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $197 |
| Teva Pharmaceuticals USA, Inc. | 10 | $189 |
| Supernus Pharmaceuticals, Inc. | 6 | $121 |
| Axsome Therapeutics, Inc. | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 6 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $92 |
| Lundbeck LLC | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Indivior Inc. | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Almatica Pharma LLC | 2 | $34 |
| Tris Pharma Inc | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Harmony Biosciences LLC | 2 | $22 |
| Merck | 1 | $18 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$227,373
How this compares
$235,304 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $117,431 |
| QuviviqDaridorexant Hcl | 24 | $11,488 |
| Loreev XrLorazepam | 11 | $5,010 |
| TrintellixVortioxetine Hydrobromide | 12 | $4,459 |
| Vilazodone Hcl | 35 | $1,560 |
| Bupropion Hcl SrBupropion Hcl | 13 | $841 |
| Duloxetine Hcl | 20 | $819 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 19 | $759 |
| Quetiapine Fumarate | 49 | $706 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $616 |
| Bupropion XlBupropion Hcl | 28 | $443 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $383 |
| Eszopiclone | 14 | $365 |
| Clonazepam | 23 | $285 |
| Trazodone Hcl | 27 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $189 | $117,43111 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $67 | $11,48824 claims |
| Almatica Pharma LLCLoreev Xr | $34 | $5,01011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $197 | $4,45912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Parkersburg
- Tarrah HollidayAtlantic$421K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
- Daniel WesemannDavenport$15K
- Melissa KonkenSioux City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.